Respiratory Research (Dec 2022)

The Establishment of China Bronchiectasis Registry and Research Collaboration (BE-China): Protocol of a prospective multicenter observational study

  • Yong-Hua Gao,
  • Hai-Wen Lu,
  • Bei Mao,
  • Wei-Jie Guan,
  • Yuan-Lin Song,
  • Yuan-Yuan Li,
  • Dao-Xin Wang,
  • Bin Wang,
  • Hong-Yan Gu,
  • Wen Li,
  • Hong Luo,
  • Ling-Wei Wang,
  • Fan Li,
  • Feng-Xia Guo,
  • Min Zhang,
  • Zhi-Jun Jie,
  • Jing-Qing Hang,
  • Chao Yang,
  • Tao Ren,
  • Zhi Yuan,
  • Qing-Wei Meng,
  • Qin Jia,
  • Yu Chen,
  • Rong-Chang Chen,
  • Jie-Ming Qu,
  • Jin-Fu Xu

Journal volume & issue
Vol. 23, no. 1
pp. 1 – 14


Read online

Abstract Background Bronchiectasis is a highly heterogeneous chronic airway disease with marked geographic and ethnic variations. Most influential cohort studies to date have been performed in Europe and USA, which serve as the examples for developing a cohort study in China where there is a high burden of bronchiectasis. The Establishment of China Bronchiectasis Registry and Research Collaboration (BE-China) is designed to: (1) describe the clinical characteristics and natural history of bronchiectasis in China and identify the differences of bronchiectasis between the western countries and China; (2) identify the risk factors associated with disease progression in Chinese population; (3) elucidate the phenotype and endotype of bronchiectasis by integrating the genome, microbiome, proteome, and transcriptome with detailed clinical data; (4) facilitate large randomized controlled trials in China. Methods The BE-China is an ongoing prospective, longitudinal, multi-center, observational cohort study aiming to recruit a minimum of 10,000 patients, which was initiated in January 2020 in China. Comprehensive data, including medical history, aetiological testing, lung function, microbiological profiles, radiological scores, comorbidities, mental status, and quality of life (QoL), will be collected at baseline. Patients will be followed up annually for up to 10 years to record longitudinal data on outcomes, treatment patterns and QoL. Biospecimens, if possible, will be collected and stored at − 80 °C for further research. Up to October 2021, the BE-China has enrolled 3758 patients, and collected 666 blood samples and 196 sputum samples from 91 medical centers. The study protocol has been approved by the Shanghai Pulmonary Hospital ethics committee, and all collaborating centers have received approvals from their local ethics committee. All patients will be required to provide written informed consent to their participation. Conclusions Findings of the BE-China will be crucial to reveal the clinical characteristics and natural history of bronchiectasis and facilitate evidence-based clinical practice in China. Trial registration Registration Number in NCT03643653